Skip to main content

Table 3 Median time from specimen collection to treatment initiation, by diagnostic method and disease classification (n = 686)

From: Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa

 

Early cohort (n = 256)

Late cohort (n = 430)

P value

Diagnosis method

 Xpert MTB/RIF

17 (9–46) (n = 107)

13 (7–28) (n = 282)

< 0.001

 GenoType MTBDRplus line probe assay

38 (23–51) (n = 129)

15 (7–36) (n = 129)

 

 Phenotypic drug susceptibility testing

81 (28–97) (n = 7)

n/a

 

Disease classification

 RR-TB by Xpert MTB/RIF

13 (9–30) (n = 57)

10 (7–17) (n = 188)

< 0.001

 RIF mono-resistant TB

48 (30–75) (n = 48)

13 (2–38) (n = 62)

 

 MDR-TB

34 (14–49) (n = 147)

22 (8–37) (n = 128)

 

 XDR-TB

42 (35–70) (n = 3)

36 (14–61) (n = 4)

 
  1. MDR-TB Multi-drug resistant, XDR-TB Extensively drug resistant TB, RR-TB Rifampicin resistant TB, RIF rifampicin